ASH 2015 | ASH 2015 highlights by Prof. Michael Hallek
Michael Hallek
• 4 Dec 2015
Michael Hallek, MD from the University of Cologne, Cologne, Germany, provides an overview of main chronic lymphocytic leukemia (CLL) studies being presented at the America Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. Prof. Hallek discusses the new data being presented on venetoclax (ABT-199), a Bcl-2 inhibitor, in CLL patient with 17p deletion or mutated p53, and inhibitors targeting well-known CLL targets, such as Bruton’s tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K), as single-agents or in combinations with other therapies.
